1. Reply to 'Arsenic patent keeps drug for rare cancer out of reach for many'.

    Nature Medicine 13(11):1278 (2007) PMID 17987017

  2. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo.

    Blood 99(4):1356 (2002) PMID 11830487

    This study identified missense mutations in the ligand binding domain of the oncoprotein PML-RARalpha in 5 of 8 patients with acute promyelocytic leukemia (APL) with 2 or more relapses and 2 or more previous courses of all-trans retinoic acid (RA)-containing therapy. Four mutations were novel (L...
  3. Acute renal failure associated with the retinoic acid syndrome in acute promyelocytic leukemia

    American Journal of Kidney Diseases 27(1):134 (1996)

    All- trans-retinoic acid is an effective agent to induce remission in patients with acute promyelocytic leukemia (APL). Unlike conventional chemotherapy, this drug exerts its effect by inducing differentiation of immature leukemic cells. A distinctive clinical syndrome characterized b...
  4. Clinical trials of gallium nitrate in patients with cancer-related hypercalcemia

    Seminars in Oncology 18(4):26 (1991)

  5. Induction of profound hypouricemia by a non-sedating thiobarbiturate

    Metabolism 38(6):550 (1989)

    5-[N-phenylcarboxamido]-2-thiobarbituric acid (merbarone) is a non-sedating derivative of thiobarbituric acid originally developed for anticancer use. In the initial clinical study, a profound reduction in serum uric acid was observed. In 20 patients who received five daily doses of merbaro...
  6. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure

    The American Journal of Medicine 66(2):226 (1979)

    Factor VIII/von Willebrand factor antigen and von Willebrand factor activity (ristocetin assay) were studied in 12 patients in renal failure. A dramatic increase in both activities was observed (antigen 315 ± 30 per cent in patients versus 104 ± 9 per cent in control subjects; activity...